CN102796156B - Adenosine cyclophosphate double-molecule meglumine compound and preparation method thereof - Google Patents

Adenosine cyclophosphate double-molecule meglumine compound and preparation method thereof Download PDF

Info

Publication number
CN102796156B
CN102796156B CN201210314213.2A CN201210314213A CN102796156B CN 102796156 B CN102796156 B CN 102796156B CN 201210314213 A CN201210314213 A CN 201210314213A CN 102796156 B CN102796156 B CN 102796156B
Authority
CN
China
Prior art keywords
camp
meglumine
compound
preparation
molecule
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201210314213.2A
Other languages
Chinese (zh)
Other versions
CN102796156A (en
Inventor
宁辉
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zhejiang Zhongyan Pharmaceutical Technology Co ltd
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to CN201210314213.2A priority Critical patent/CN102796156B/en
Publication of CN102796156A publication Critical patent/CN102796156A/en
Application granted granted Critical
Publication of CN102796156B publication Critical patent/CN102796156B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The invention relates to an adenosine cyclophosphate double-molecule meglumine compound and a preparation method thereof, and provides a compound formed by 1 molecule of adenosine cyclophosphate and 2 molecules of meglumine, a preparation method thereof and a medicinal composition comprising the denosine cyclophosphate double-molecule meglumine compound. The water solubility and the stability of the compound are more excellent than those of the conventional compounds.

Description

CAMP two meglumine compounds and preparation method thereof
Technical field
The present invention relates to a kind of cAMP two meglumine compounds and preparation method thereof, belong to the synthetic field of pharmaceutical chemistry.
Background technology
CAMP is a kind of protein kinase activator, belongs to the derivative of Nucleotide.It is a kind of important substance with physiologically active extensively existing in human body, is generated under adenosine cyclase catalysis by Triphosaden, can regulate the several functions activity of cell.As the second messenger of hormone, in cell, bring into play the effect of hormone regulation physiological function and substance metabolism, change the function of cytolemma, impel the calcium ion in sarcoplasm matter to enter myofiber, thereby enhancing myocardial contraction, and promote the oxidasic activity of respiratory chain, and improve myocardial anoxia, alleviate coronary heart disease symptom and improve electrocardiogram(ECG.In addition, synthetic adjusting to sugar, metabolism of fat, nucleic acid, protein etc. plays an important role.
Meglumine, molecular weight is 195, soluble in water, there is suitable alkalescence and certain reductibility, and safe, nontoxic, with the compound combination that contains phenolic hydroxyl group, after salify to skin, mucous membrane, organize nonirritant, therefore be suitable as very much the solubility promoter of medicine, improve the water-soluble of principal constituent.
CAMP is slightly soluble in water, adds meglumine can increase its solvability in cAMP.Meglumine Adenosine Cyelophosphate (1: 1 compound of cAMP and meglumine, chemical name: meglumine cyclic adenylate, be called for short MCA, trade(brand)name, meglumine cyclic adenylate, MCA) injection liquid, be a kind of cardiac drug, be used for the treatment of heart failure, myocarditis, sick sinus syndrome, coronary heart disease, myocarditis, and ARR assisting therapy.Because of its determined curative effect, effect is unique in recent years, and security is good, is widely used in clinical.But it is water-soluble, stability is still not enough, impurity showed increased in the time of standing storage, and also it is water-soluble not, can not be used for oral preparations etc.Therefore this area also needs a kind of stable cAMP medicine, can be for the applicable illness of cAMP, and Simultaneous Stabilization, safety, effective, good water solubility.
Summary of the invention
The object of the invention is to address the above problem, the compound of a kind of cAMP and meglumine is provided, i.e. cAMP two meglumine compounds, this compound is safer, stable, effective, has better water-soluble simultaneously.
Another object of the present invention is to provide the preparation method of described compound.
The present invention also provides a kind of pharmaceutical composition, and it comprises described compound and pharmaceutically acceptable carrier.
Another object of the present invention is to provide the application of described compound in preparation treatment heart failure, myocarditis, sick sinus syndrome, coronary heart disease, myocarditis and antiarrhythmic medicament.
As previously mentioned, it is known in the art that cAMP and meglumine share, and their 1: 1 salifies are for injection.But in Meglumine Adenosine Cyelophosphate solution, along with the prolongation of shelf time, cAMP can be separated out gradually, liquid is occurred rotten, muddy, as changing small being difficult for, it is discovered, there will be serious untoward reaction if deliver medicine to patient, thereby affect the curative effect of medicine, affect the security of medication simultaneously.Meglumine cyclic adenosine injection is in solution state preservation process, easily meeting light changes, make drug degradation, because its clinical anaphylaxis increase, curative effect decline, and Meglumine Adenosine Cyelophosphate solution is subject to the affecting oxidation, polymerization of environmental factors and medicines structure is changed.
The inventor, through concentrating on studies, finds, under 60-70 DEG C of heating 0.5-2 hour, the meglumine of 1 molecule cAMP and 2 molecules to be synthesized to a compound.Find by analysis, under heating condition, meglumine not only with the phosphatase reaction of cAMP, and can react with the weakly acidic phenolic group of embodiment, cAMP two meglumine compounds are so just formed, the compound stability forming and water-soluble better is better cAMP medicinal forms.And the control of temperature is critical, temperature is too low, can not form described compound, only may form 1: 1 compound; Excess Temperature, has impact to the stability of cAMP and meglumine self, and impurity is too much.Based on above-mentioned discovery, complete the present invention.
Described compound structure is as follows:
The preparation method of compound of the present invention, simple process, it comprises:
Meglumine and DMF are joined in cAMP suspension and stirred, then at 60-70 DEG C, be heated to clarification, the direct described compound of acquisition after lyophilize.
Wherein, described cAMP suspension joins cAMP in water, methyl alcohol or ethanol and is prepared from, and the mol ratio of meglumine and cAMP is 2-10: 1.Usually, be 0.5-2 hour heat-up time.
The present invention also provides a kind of pharmaceutical composition, and it comprises described compound and pharmaceutically acceptable carrier, can be mixed with the form through any suitable administration, can prepare pharmaceutically acceptable any pharmaceutical dosage form, comprises injection, for example powder pin, injection liquid; Oral preparations, such as tablet, capsule, granule, oral liquid, powder agent, pill, sublingual administration agent etc.; Parenteral eye drop, nasal drops, [Dan etc. can be also the controlled release agent types of above various formulations.
Pharmaceutical carrier can comprise vehicle or thinner, for example, in Microcrystalline Cellulose, lactose, pregelatinized Starch, starch, dextrin, calcium phosphate, sucrose, dextran, N.F,USP MANNITOL, sorbyl alcohol, glucose, fructose, water, polyoxyethylene glycol, propylene glycol, glycerine, cyclodextrin, cyclodextrin derivative one or more; Tackiness agent, for example, in polyvinylpyrrolidone, methylcellulose gum, Walocel MT 20.000PV, HPMC, hydroxypropylcellulose, Natvosol, gelatin, guar gum, xanthan gum one or more; Lubricant, for example, in Magnesium Stearate, stearic acid, talcum powder, stearyl fumarate, Sodium Lauryl Sulphate BP/USP one or more; Disintegrating agent, for example, in sodium starch glycolate, low-substituted hydroxypropyl cellulose, Xylo-Mucine, cross-linked polyvinylpyrrolidone, croscarmellose sodium, crosslinked carboxymethyl fecula sodium, pregelatinized Starch one or more; Tensio-active agent, for example, in sodium lauryl sulphate, Tween-80 one or more; PH adjusting agent or buffer reagent, one or more of for example phosphate buffered saline buffer, citric acid, Trisodium Citrate, acetate buffer, dilute hydrochloric acid, sodium carbonate, sodium hydroxide; Sanitas, for example, in Sodium Benzoate, potassium sorbate, methyl p-hydroxybenzoate, propylparaben one or more; Stablizer and oxidation inhibitor, for example, in Calcium Disodium Edetate, S-WAT, vitamins C one or more; Seasonings, for example, in maltose alcohol, fructose, sucrose, soluble saccharin, flavoring orange essence, strawberry flavour one or more; And other auxiliary material.
It is also understood that in the time that formulation is tablet or capsule, can be film dressing.For the material of film dressing, comprise applicable Drug coating, for example HPMC, Natvosol, hydroxypropylcellulose, hydroxypropyl methylcellulose phthalate; Softening agent, for example polyoxyethylene glycol, triethyl citrate; Solubilizing agent, as Polyoxyethylene Sorbitan Monooleate; Pigment, as titanium dioxide, various ferric oxide, pink pigment, etc.
Pharmaceutical composition as above can also comprise other and have the material of pharmaceutical active, and for example, for the medicine of disease as mentioned above, the pharmaceutical composition that forms a kind of compound carrys out combination therapy.
The advantage of compound of the present invention is that it is water-soluble, stability is better, has also kept the activity of cAMP self simultaneously, and this is that it is with respect to cAMP and the outstanding feature of cAMP one meglumine salt.This is useful especially for preparation and storage pharmaceutical preparation.
Compound of the present invention has the pharmacological action identical with cAMP.In heart failure, myocarditis, sick sinus syndrome, coronary heart disease, myocarditis and ARR correlation model, by described salt and cAMP and cAMP one comparing property of meglumine salt test, find that they have substantially suitable effect, do not exist notable difference.This shows, is consistent with the knowledge of this area, and salify can't change the activity of medicine.
Compound water soluble of the present invention, stability are better, and preparation method is easy, are applicable to scale operation, are suitable for preparing various types of pharmaceutical dosage forms, for effective application of cAMP provides better selection.
Embodiment
Be further detailed below by embodiment, but the present invention is not limited in these embodiment.
Embodiment 1. cAMP two meglumines and preparations thereof
Getting 0.30g (0.911mmol) cAMP adds in 20ml ethanol, stir and heat and make to dissolve completely, add wherein 0.49g (2.53mmol) meglumine, slowly add and stir, after completing, at 65 DEG C, heat 1.8 hours, to solution clarification, lyophilize, obtain the cAMP two meglumine 0.607g (yields: 93.5%) of white powder.
1HNMR(DMSO-d 6)δ(ppm):0.767~0.785(4H,t),1.134~1.160(21H,m),1.450~1.466(4H,m),2.514(4H,s),2.815~2.843(2H,m),2.946~2.997(2H,m),3.312~3.319(4H,m),3.385~3.427(8H,m),3.640~3.654(6H,m),3.835~3.844(2H,m),3.931~3.952(4H,m),4.154(2H,s),4.371(2H,s),6.658~6.616(6H,m),7.082(2H,d)。
13CNMR(DMSO-d 6)δ(ppm):13.967,22.117,25.597,29.137,31.289,33.289,51.435,53.465,63.461,66.956,67.719,68.864,70.283,113.474,121.044,130.304,141.446。
Embodiment 2. cAMP two meglumines and preparations thereof
Getting 0.50g (1.519mmol) cAMP adds in 35ml water, stir and heat and make to dissolve completely, add wherein 1.20g (6.148mmol) meglumine, slowly add and stir, after completing, at 70 DEG C, heat 0.8 hour, to solution clarification, lyophilize, obtain the cAMP two meglumine 0.987g (yields: 90.8%) of white powder.
CAMP two meglumines of above-mentioned preparation or its hydrate, through proton nmr spectra, carbon spectrum analysis, are all consistent with embodiment 1.
Embodiment 3. Accelerated stability tests
CAMP at high temperature can decompose conventionally, produces impurity impurity, is referred to as total related substance, under hot conditions, measures the wherein content of total related substance, analyzes its stability.
Get in 50 DEG C of baking ovens of appropriate cAMP two meglumine, respectively at sampling in the 5th, 10 days, measure total related substance wherein.
Adopt high-efficient liquid phase chromatogram technique analysis, test-results is in table 1.
Table 1
Measurement result shows, 50 DEG C of cAMP two meglumine high temperature are placed 10 days, and total its related substances increases to some extent, but that the overwhelming majority still keeps is stable, more more stable than cAMP one meglumine.
Embodiment 4. soluble tests
Through rough determination comparison, cAMP two meglumines and cAMP water-soluble (normal temperature and pressure) are compared as follows table 2.
Table 2
Compound Water-soluble (mg/ml water)
CAMP two meglumines Be less than 1
CAMP one meglumine Be greater than 8
CAMP Be greater than 20
As can be seen from Table 2, the water-soluble cAMP that is far longer than of cAMP two meglumines of the present invention, is also greater than cAMP one meglumine, shows the water-soluble of excellence.
The lyophilized injectable powder of embodiment 4. cAMP two meglumines
CAMP two meglumines 30g
N.F,USP MANNITOL 120g
Buffer reagent In right amount
Water for injection Add to 2500ml
CAMP two meglumines, the N.F,USP MANNITOL of getting recipe quantity add 2300ml water for injection and dissolve, regulating pH is 5~6, injects water to 2500ml, with filtering with microporous membrane degerming, under hundred grades of conditions, carry out in sterile filling to 1000 cillin bottle, check after loading amount and add plug, box out, glass bottle is sent into in the freeze drying box of having sterilized, to carry out freeze-drying dry, pre-freeze 5 hours, temperature drops to-35 DEG C, distils for the first time 8 hours, and temperature rise is to-5 DEG C; Distil for the second time 7 hours, temperature rise to 25 DEG C, takes out after vacuum gland or inflated with nitrogen gland, and jewelling lid labeling gets product, and every bottle of freeze-dried powder is containing cAMP two meglumine 30mg.
Embodiment 5. cAMP two meglumine injections
Meglumine cyclic adenylate salt described in embodiment 1-2 and conventional pharmaceutical excipient are mixed, press the preparation method of injection, be prepared into freeze-dried powder injection or injection liquid, the meglumine cyclic adenylate salt that every bottle of freeze-dried powder injection or injection liquid contain 0.1~500mg.
Embodiment 6. cAMP two meglumine tablet/capsules
Meglumine cyclic adenylate salt described in embodiment 1-2 and conventional pharmaceutical excipient are mixed, by the preparation method of tablet or capsule, be prepared into tablet or capsule, the meglumine cyclic adenylate salt that every tablet or capsule contain 0.1~500mg.

Claims (6)

1. the cAMP being shown below and the compound of meglumine, its meglumine by 1 molecule cAMP and 2 molecules forms
2. the preparation method of the compound of claim 1, comprising: meglumine is joined in cAMP suspension and stirred, then at 60-70 DEG C, be heated to clarification, directly obtain described compound after lyophilize; Wherein the mol ratio of meglumine and cAMP is 2-10: 1.
3. the preparation method of claim 2, wherein said cAMP suspension joins cAMP in water, methyl alcohol or ethanol and is prepared from.
4. the arbitrary preparation method of claim 2-3, be wherein 0.5-3 hour heat-up time.
5. a pharmaceutical composition, the compound that comprises claim 1 and pharmaceutically acceptable carrier.
6. the application of the compound of claim 1 in preparation treatment heart failure, sick sinus syndrome, coronary heart disease, myocarditis and ARR medicine.
CN201210314213.2A 2012-08-24 2012-08-24 Adenosine cyclophosphate double-molecule meglumine compound and preparation method thereof Active CN102796156B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201210314213.2A CN102796156B (en) 2012-08-24 2012-08-24 Adenosine cyclophosphate double-molecule meglumine compound and preparation method thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201210314213.2A CN102796156B (en) 2012-08-24 2012-08-24 Adenosine cyclophosphate double-molecule meglumine compound and preparation method thereof

Publications (2)

Publication Number Publication Date
CN102796156A CN102796156A (en) 2012-11-28
CN102796156B true CN102796156B (en) 2014-07-30

Family

ID=47195487

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201210314213.2A Active CN102796156B (en) 2012-08-24 2012-08-24 Adenosine cyclophosphate double-molecule meglumine compound and preparation method thereof

Country Status (1)

Country Link
CN (1) CN102796156B (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103613626B (en) * 2013-11-29 2015-10-14 湖北美林药业有限公司 A kind of adenosine cyclophosphate compound and meglumine adenosine cyclophosphate medicine composition thereof

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS49116096A (en) * 1972-07-25 1974-11-06
US3872082A (en) * 1971-05-19 1975-03-18 Boehringer Mannheim Gmbh Substituted purineribofuranoside-3,5-cyclophosphate compounds and process for their preparation
CN1459288A (en) * 2003-06-18 2003-12-03 赵琛 Cyclophosphadenosine glucosamine infusion prepn., and its prepn. process, and method for testing contents thereof
CN1579413A (en) * 2004-02-11 2005-02-16 江卫世 Meglumine adenosine cyclophosphate for injection and its preparing method
CN1923180A (en) * 2006-09-22 2007-03-07 江苏万邦生化医药股份有限公司 Meglumine cyclic adenosine for injecta and its preparing process
CN101455631A (en) * 2009-01-06 2009-06-17 湖北德康药业有限公司 Meglumine cyclic adenosine injection and preparation technique thereof
CN102258531A (en) * 2011-04-12 2011-11-30 宁辉 Medicinal composition containing adenosine cyclophosphate and meglumine and preparation method thereof
CN102488650A (en) * 2011-12-19 2012-06-13 王保明 Adenosine cyclophosphate pharmaceutical composition and preparation method thereof

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3872082A (en) * 1971-05-19 1975-03-18 Boehringer Mannheim Gmbh Substituted purineribofuranoside-3,5-cyclophosphate compounds and process for their preparation
JPS49116096A (en) * 1972-07-25 1974-11-06
CN1459288A (en) * 2003-06-18 2003-12-03 赵琛 Cyclophosphadenosine glucosamine infusion prepn., and its prepn. process, and method for testing contents thereof
CN1579413A (en) * 2004-02-11 2005-02-16 江卫世 Meglumine adenosine cyclophosphate for injection and its preparing method
CN1923180A (en) * 2006-09-22 2007-03-07 江苏万邦生化医药股份有限公司 Meglumine cyclic adenosine for injecta and its preparing process
CN101455631A (en) * 2009-01-06 2009-06-17 湖北德康药业有限公司 Meglumine cyclic adenosine injection and preparation technique thereof
CN102258531A (en) * 2011-04-12 2011-11-30 宁辉 Medicinal composition containing adenosine cyclophosphate and meglumine and preparation method thereof
CN102488650A (en) * 2011-12-19 2012-06-13 王保明 Adenosine cyclophosphate pharmaceutical composition and preparation method thereof

Also Published As

Publication number Publication date
CN102796156A (en) 2012-11-28

Similar Documents

Publication Publication Date Title
JP3889481B2 (en) Pharmaceutical composition
CN102391250A (en) Dabigatran compound and preparation method and medicinal composition thereof
US20230190732A1 (en) Pharmaceutical composition containing nitroxoline prodrug, and preparation method and application therefor
CN101585859B (en) Novel scutellarin derivative as well as preparation method and pharmaceutical composition thereof
US20190247342A1 (en) Alpha-Ketobutyrate, 2-Hydroxybutyrate, and Alpha-Ketoglutarate for Stimulating Hair Growth
CN104719910A (en) Solid dispersion combination of EGCG (epigallocatechin gallate) with thermal stability and preparation method of solid dispersion combination and application in preparation of solid dispersion combination
TWI343262B (en) Rapidly disintegrating lyophilized oral formulations of a thrombin receptor antagonist
CN100584835C (en) Novel medicinal salt for cinepazide and preparation method thereof
CN102481287B (en) Pharmaceutical composition of temozolomide comprising vitamin c or vitamin c derivative and preparation method thereof
JP3253302B2 (en) Parenteral solution containing 3-dialkylaminoethoxybenzoyl-benzofuran
CN100490819C (en) Medicines of different characters and their preparation and use
CN102796156B (en) Adenosine cyclophosphate double-molecule meglumine compound and preparation method thereof
CN104688676B (en) Andrographolide concentrated type liquid formula and its medical usage
CN103980279B (en) A kind of methotrexate compound and methotrexate for injection
CN107365272A (en) A kind of novel imidazole class compound and preparation method thereof and application medically
CN115124532B (en) Rhein and matrine eutectic crystal, preparation method, composition and application thereof
CN102093234B (en) Tromethamine salt compound of dibasic ester acid, preparation method and medicinal application thereof
CN103183722A (en) Glyoxalase I inhibitor, preparation method and medical application thereof
CN101514189B (en) Glycin diazole tromethamine compound as well as preparation method and medicament application thereof
CN102008461B (en) A kind of ibuprofen drug composite for injection
CN115124420A (en) Rhein and matrine eutectic crystal hydrate, preparation method, composition and application thereof
CN1729988A (en) Composite medicine of creatine phosphate sodium and magnesium salt
CN113521020B (en) A solid dosage form of adefovir containing water soluble acid
CN103570679A (en) Dabigatran etexilate gluconate, preparation method and application thereof
CN112294777B (en) Ivabradine hydrochloride sustained-release preparation and preparation method and application thereof

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
EE01 Entry into force of recordation of patent licensing contract

Application publication date: 20121128

Assignee: SHANDONG LUYE PHARMACEUTICAL Co.,Ltd.

Assignor: Ning Hui

Contract record no.: 2014370000117

Denomination of invention: Adenosine cyclophosphate double-molecule meglumine compound and preparation method thereof

License type: Common License

Record date: 20140711

LICC Enforcement, change and cancellation of record of contracts on the licence for exploitation of a patent or utility model
TR01 Transfer of patent right
TR01 Transfer of patent right

Effective date of registration: 20240418

Address after: Room 202, East Building C, Headquarters Center, No. 23 Guangfu East Street, Houtang Community, Jiangbei Street, Dongyang City, Jinhua City, Zhejiang Province, 322100

Patentee after: Zhejiang Zhongyan Pharmaceutical Technology Co.,Ltd.

Country or region after: China

Address before: Room 202, Study Abroad Building, No. 129 Fuzhou North Road, Shibei District, Qingdao City, Shandong Province, 266034

Patentee before: Ning Hui

Country or region before: China